Atimos, aerosol 12 mcg/dose 120 doses

Pharmgroup:

The bronchodilator is a beta2-adrenomimetic selective.

Pharm Action:

Atimos is a bronchodilator drug, a selective β2-adrenoreceptor agonist with low affinity for β1-adrenoreceptors. The mechanism of action is associated with activation of adenylate cyclase, which leads to increase of cyclic AMP (cAMP) that causes activation of protein kinase A.

Activated protein kinase A inhibits phosphorylation of key proteins responsible for the control of smooth muscle tone. Increased intracellular concentration of cAMP also leads to suppression of release of calcium ions from the depot. The combination of these processes leads to a bronchodilator effect.

The action of the drug is fast and prolonged. Formoterol effectively prevents bronchospasm caused by inhaled allergens, physical activity, cold air, histamine, or methacholine.

Pharmacokinetics:

Intake and distribution

About 90% of the drug can be swallowed after inhaled administration. After oral administration, it is rapidly absorbed from the gastrointestinal tract. The Cmax of formoterol in plasma is 60% 15 min after administration and decreases to 10% 24 h after administration.

Distribution
Binding of formoterol to plasma proteins is 50-65%.

Metabolism and excretion

Formoterol is metabolized by direct addition of a glucuronic acid residue and o-demethylation.

The active substance and its metabolites are completely eliminated from the body: 36-45% are eliminated in the urine, 50-56% – in the feces within 72 hours after administration.
T1/2 is 4 hours after IV and 6 hours after oral administration.

Indications

Active ingredient

How to take, the dosage

Adults, including elderly patients, are prescribed 12-24 mcg (1-2 doses) 2 times daily for treatment and prevention of Atimos.

Children 6 years of age and older are prescribed 12 mcg (1 dose) 2 times a day.

Interaction

Class Ia (quinidine, disopyramide, novocainamide) and Class III (solatol, amidarone) antiarrhythmic agents, phenothiazines, antihistamines, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants, Intravenous erythromycin, pentamidine, sultopride, vincomycin, halofantrine, bepridil may prolong the QT interval and increase the risk of ventricular arrhythmias (risk of pirouette arrhythmias).

The concomitant use of other adrenergic drugs may aggravate the side effects of Atimos.

Concomitant treatment with xanthine derivatives, glucocorticosteroids, or diuretics may increase the potential hypokalemic effects of β2-adrenomimetics. Hypokalemia may increase the risk of cardiac arrhythmias in patients receiving Napyrngeal preparations.

The β-adrenoblockers may decrease the effects of Atimos. Therefore, the drug should not be used concomitantly with β-adrenoblockers (including eye drops) unless the use is dictated by necessity.

Because of the small amount of ethanol, interactions may occur in hypersensitive patients taking disulfiram or metronidazole.

Special Instructions

If systemic treatment with inhaled adrenomimetics is required, patients with bronchial asthma should receive systemic anti-inflammatory therapy.

Hence, if treatment with Atimos is prescribed, the need for anti-inflammatory therapy should be evaluated.

Contraindications

With caution

Ischemic heart disease, myocardial infarction, exacerbation of arterial hypertension, arrhythmias, chronic decompensated heart failure, diabetes, prostatic hypertrophy, glaucoma, pregnancy.

Side effects

Musculoskeletal system:

Pregnancy use